All In Biotech

Drug Trial Radar · NCT06430528

A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Jul 19, 2024

Primary completion

Oct 2027

Study completion Jan 2028

Sponsor

Lead sponsor
University of MichiganAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
RECORDATI GROUP
First posted
May 28, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The major goal of this study is to determine the incidence of adrenal insufficiency in patients with endogenous Cushing syndrome receiving osilodrostat treatment combined with a replacement of glucocorticoid (block-and-replace approach). The investigators are also evaluating new biomarker steroids to reflect adequate osilodrostat dosing, the durability and safety, and clinical improvement during treatment.

Conditions

  • Endogenous Cushing Syndrome
  • Adrenal Insufficiency
  • Hypercortisolism

Interventions

  • OsilodrostatDrug

    Add methylprednisolone to osilodrostat therapy after first dose and continue during osilodrostat titration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of participants who experience an adrenal insufficiency event during Phase 1 (titration phase)Time frame: Through phase 1, approximately 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.